P4886 - Association Between Congenital Birth Defects and Development of MASH Cirrhosis: Insights From the National Inpatient Sample

Sarpong Boateng, MD, MPH¹, Chukwunonso Ezeani, MBBS², Prince A. Ameyaw, MD¹, Basile Njei, MD^3
1Yale New Haven Health, Bridgeport Hospital, Bridgeport, CT; ²Baton Rouge General Medical Center, Baton Rouge, LA; ³Yale University School of Medicine, New Haven, CT

Introduction: Congenital birth defects have been reported to be associated with various long-term health outcomes, including liver diseases. Metabolic Associated Steatotic Hepatitis (MASH), a severe form of Metabolic Associated Steatotic Liver Disease (MASLD), is one such condition. This study aims to examine the relationship between congenital birth defects and the development of MASH cirrhosis, considering the impact of overweight and obesity.

Methods: This retrospective study utilized data from the National Inpatient Sample (NIS) spanning 2016-2020. We identified patients with MASH cirrhosis and categorized them into (BMI less than 25 kg/m²) and non-lean (BMI ≥ 25 kg/m²) groups. We adjusted for multiple factors including age, sex, race, smoking status, cardiometabolic risk factors, hospital characteristics, admission type, year of admission, socio-economic factors, and 31 Elixhauser comorbidities. Multivariate logistic regression used to assess the association between lean and non-lean MASH cirrhosis and development of congenital birth defects classified by organ system involvement

Results: A total of 43,988 hospitalized patients with MASH cirrhosis were included, comprising 27,887 non-lean and 16,101 lean patients. The prevalence of birth defects in both groups was compared, and no significant differences were found for most congenital anomalies. However, a significant difference was observed in the chromosomal anomalies and overall birth defects after adjusting for confounding factors. Specifically, the odds of developing MASH cirrhosis were higher in non-lean patients with chromosomal anomalies, compared with lean patients (aOR: 2.36, 95% CI: 1.09–5.12, p=0.0291). Similarly, Specifically, the odds of developing MASH cirrhosis were higher in non-lean patients, compared with lean patients for overall birth defects (aOR: 1.43, 95% CI: 1.12–1.84, p=0.0046).

Discussion: Our findings indicate an increased odds of chromosomal anomalies and overall birth defects in non-lean patients with MASH cirrhosis compared to lean patients. The significant differences observed after adjusting for confounders suggest that the association between congenital birth defects and the development of MASH cirrhosis may be influenced by BMI. Moving forward, further research is needed to confirm this potential mechanism and explore potential clinical implications of these associations.


Disclosures:


Sarpong Boateng, MD, MPH¹, Chukwunonso Ezeani, MBBS², Prince A. Ameyaw, MD¹, Basile Njei, MD³. P4886 - Association Between Congenital Birth Defects and Development of MASH Cirrhosis: Insights From the National Inpatient Sample, ACG 2024 Annual Scientific Meeting Abstracts. Philadelphia, PA: American College of Gastroenterology.